NasdaqCM - Nasdaq Real Time Price USD

Belite Bio, Inc (BLTE)

Compare

59.42

+59.42

+(2.10%)

At close: January 24 at 4:00:01 PM EST

57.07

-2.35

(-3.95%)

Pre-Market: 4:32:57 AM EST

Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE)

Belite Bio, Inc ( NASDAQ:BLTE ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. 6 days ago

BLTE
+2.10%
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Fast Track designation indicates LBS-007’s potential in filling the unmet medical need of acute leukemiaLBS-007 is the Company’s investigational medicinal product for the treatment of acute leukemiaA Phase 1/2 trial in patients with relapsed or resistant acute leukemias is ongoingLBS-007, the Company’s lead asset, has been granted orphan drug designations for acute myeloid leukemia and acute lymphocytic leukemia by the U.S. FDA TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScienc

GlobeNewswire last month

6696.TWO

BLTE
+2.10%
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivo

GlobeNewswire 2 months ago

BLTE
+2.10%
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2024. Webcast Informatio

GlobeNewswire 2 months ago

BLTE
+2.10%
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in A

GlobeNewswire 2 months ago

BLTE
+2.10%
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will present data from its completed Phase II adolescent Stargardt disease trial at the American Academy of Ophthalmology Annual Meeting (AAO 2024) being held October 18-21, 2024,

GlobeNewswire 3 months ago

BLTE
+2.10%
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hendrik P.N. Scholl, MD, MA, Chief Medical Officer of Belite Bio, will participate in the “Ocular Drug Development” panel discussion at the Maxim Group 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 11:

GlobeNewswire 3 months ago

BLTE
+2.10%
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held September 24th and 25th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3ZHifQf The company presentations will be available 24/7 for 90 days. Sep

GlobeNewswire 3 months ago

AZN

AZNCF

BDOUF
Here's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 4 months ago

BLTE
+2.10%
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respo

GlobeNewswire 4 months ago

FPAFF

FPAFY

SSEZF
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

Phase 2/3 of the DRAGON II trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in approximately 60 adolescent STGD1 subjects across the U.S., U.K., and JapanPhase 1b of DRAGON II trial to evaluate pharmacokinetics and pharmacodynamics of Tinlarebant in Japanese subjects was recently completedTinlarebant granted Orphan Drug and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1Pivotal global Phase 3 trial of Tinlarebant in GA subjects (“PHOENIX”) is ongo

GlobeNewswire 4 months ago

BLTE
+2.10%
Belite Bio to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details for the presentations are as follows: H.C. Wainwright 26th Annual Global Investment Conference (New York, New York) Septem

GlobeNewswire 4 months ago

BLTE
+2.10%
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its bo

GlobeNewswire 4 months ago

BLTE
+2.10%
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD)Phase 1b & 2/3 (“DRAGON II”) trial of Tinlarebant in adolescent STGD1 patients has been initiated and have completed enrollment for Phase 1b with six subjects in JapanTinlarebant granted Orphan Drug and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1Pivotal globa

GlobeNewswire 5 months ago

BLTE
+2.10%
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata, Chief Scientific Officer of Belite Bio, will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. A webcast of the presentation will be available on Thursday,

GlobeNewswire 5 months ago

BLTE
+2.10%
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the second quarter ended June 30, 2024. Webcast InformationDate:

GlobeNewswire 5 months ago

BLTE
+2.10%
Belite Bio to Present at the JonesHealthcare Seaside Summit

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata, Chief Scientific Officer of Belite Bio, will participate in the JonesHealthcare Seaside Summit in Encinitas, CA, and present a corporate update on Monday, July 15, 2024, at 1:00 pm PT. A webcast of the

GlobeNewswire 6 months ago

BLTE
+2.10%
Estimating The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)

Key Insights Belite Bio's estimated fair value is US$51.94 based on 2 Stage Free Cash Flow to Equity With US$49.96...

Simply Wall St. 7 months ago

BLTE
+2.10%
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD)Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar baseline characteristics (aged ≤18 years) (p<0.001)In the Phase 2 trial,

GlobeNewswire 7 months ago

BLTE
+2.10%
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference being held virtually on May 21 and 22, 2024. The Company will host a fireside chat at 3:00 pm ET on

GlobeNewswire 8 months ago

BLTE
+2.10%

Performance Overview

Return	BLTE	MSCI WORLD
YTD	-4.11%	+3.69%
1-Year	+30.31%	+19.90%
3-Year	+375.36%	+29.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Belite Bio, Inc (BLTE)

Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE)

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

Here's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn Situation

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

Belite Bio to Participate in Three Upcoming Investor Conferences

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Belite Bio to Present at the JonesHealthcare Seaside Summit

Estimating The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

Performance Overview